aslan pharmaceuticals (aslan, 6497.tt) is a clinical-stage oncology-focused biopharmaceutical company developing novel therapeutics for global markets. aslan targets diseases that are both highly prevalent in asia and orphan indications in the united states and europe. led by a senior management team with extensive experience in global and regional development and commercialization, aslan is headquartered in singapore and has offices in taiwan and china. aslan’s portfolio is comprised of four product candidates which target validated growth pathways applied to new patient segments, novel immune checkpoints and novel cancer metabolic pathways. aslan’s partners include array biopharma, bristol-myers squibb, almirall and csl.
Company profile
Ticker
ASLN
Exchange
Website
CEO
Carl Firth
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
ASLN stock data
Latest filings (excl ownership)
6-K
Aslan Pharmaceuticals Announces Positive Interim Results from Phase 2 Study of Eblasakimab In Dupilumab-experienced Atopic Dermatitis Patients
22 Apr 24
6-K
Aslan Pharmaceuticals Announces Receipt of Nasdaq Notice
19 Apr 24
424B5
Prospectus supplement for primary offering
12 Apr 24
6-K
Amendment No. 2 to the Open Market Sale Agreementsm
12 Apr 24
S-8
Registration of securities for employees
12 Apr 24
20-F
2023 FY
Annual report (foreign)
12 Apr 24
6-K
Aslan Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
12 Apr 24
EFFECT
Notice of effectiveness
1 Apr 24
D
$5.00 mm in options / securities to be acquired, sold $5.00 mm, 4 investors
28 Mar 24
F-3
Shelf registration (foreign)
25 Mar 24
Latest ownership filings
SC 13G
INTRACOASTAL CAPITAL, LLC
21 Mar 24
SC 13G
Lind Global Fund II LP
19 Mar 24
SC 13G/A
K2 HealthVentures Equity Trust LLC
14 Feb 24
SC 13G/A
BIOTECHNOLOGY VALUE FUND L P
14 Feb 24
SC 13G
UBS Group AG
6 Feb 24
SC 13G/A
TANG CAPITAL PARTNERS LP
2 Jan 24
SC 13G/A
TANG CAPITAL PARTNERS LP
13 Jul 23
SC 13G
K2 HealthVentures Equity Trust LLC
20 Mar 23
SC 13G
BIOTECHNOLOGY VALUE FUND L P
6 Mar 23
SC 13G/A
TANG CAPITAL PARTNERS LP
14 Feb 23
Financial summary
Quarter (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Institutional ownership, Q2 2023
13F holders | Current |
---|---|
Total holders | 24 |
Opened positions | 14 |
Closed positions | 0 |
Increased positions | 2 |
Reduced positions | 1 |
13F shares | Current |
---|---|
Total value | 24.37 bn |
Total shares | 102.64 mm |
Total puts | 100.00 |
Total calls | 1.34 k |
Total put/call ratio | 0.1 |
Largest owners | Shares | Value |
---|---|---|
Biotechnology Value Fund L P | 42.44 mm | $35.52 mm |
Tang Capital Partners | 26.82 mm | $0.00 |
K2 HealthVentures Equity Trust | 26.47 mm | $110.75 mm |
Vivo Capital | 2.84 mm | $10.37 bn |
Tang Capital Management | 1.13 mm | $4.12 bn |
BVF | 1.05 mm | $3.83 bn |
Parkman Healthcare Partners | 506.62 k | $1.85 bn |
Temasek | 335.62 k | $1.22 bn |
Sio Capital Management | 254.15 k | $927.65 mm |
Citadel Advisors | 172.46 k | $629.49 mm |
News
12 Health Care Stocks Moving In Friday's After-Market Session
26 Apr 24
HC Wainwright & Co. Reiterates Buy on ASLAN Pharma, Maintains $9 Price Target
23 Apr 24
Aslan Pharmaceuticals Reports Interim Results From Phase 2 Study Of Eblasakimab In Dupilumab-Experienced Atopic Dermatitis Patients
22 Apr 24
HC Wainwright & Co. Reiterates Buy on ASLAN Pharma, Maintains $9 Price Target
15 Apr 24
Piper Sandler Reiterates Overweight on ASLAN Pharma, Lowers Price Target to $10
13 Mar 24
Press releases
ASLAN Pharmaceuticals Announces Positive Interim Results From Phase 2 Study of Eblasakimab in Dupilumab-Experienced Atopic Dermatitis Patients
22 Apr 24
ASLAN Pharmaceuticals Announces Receipt of Nasdaq Notice
19 Apr 24
ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
12 Apr 24
Aslan Pharmaceuticals to Present at the 2nd Annual H.C. Wainwright Autoimmune and Inflammatory Disease Virtual Conference: Skin Diseases, Conditions and Disorders
27 Mar 24
ASLAN Pharmaceuticals Announces $5 Million Registered Direct Offering
12 Mar 24